Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001

Nature

Volumn 482, Issue 7383, 2012, Pages 116-119

  Devore, Natasha M ^a   Scott, Emily E ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; CYTOCHROME P450 17; GALETERONE; HEME; STEROID;

CANCER; CATALYSIS; CELL ORGANELLE; CRYSTAL STRUCTURE; DRUG; ENZYME ACTIVITY; HOMOLOGY; HYDROGEN; HYDROXIDE; INHIBITION; INHIBITOR; NUMERICAL MODEL; STEROID; X-RAY;

DRUG BINDING; ENZYME MECHANISM; ENZYME STRUCTURE; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN TISSUE; HYDROGEN BOND; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; REVIEW; X RAY CRYSTALLOGRAPHY;

ANDROSTADIENES; ANDROSTENOLS; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; BIOCATALYSIS; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; HUMANS; HYDROGEN BONDING; LIGANDS; MALE; MODELS, MOLECULAR; PROSTATIC NEOPLASMS; PROTEIN CONFORMATION; RECEPTORS, ANDROGEN; STEROID 17-ALPHA-HYDROXYLASE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84856477784     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature10743     Document Type: Review

References (43)

1. Miller, W. L. & Auchus, R. J. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr. Rev. 32, 81-151 (2011).
2. Attard, G., Reid, A. H., Olmos, D. & de Bono, J. S. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res. 69, 4937-4940 (2009).
3. Yap, T. A., Carden, C. P., Attard, G. & de Bono, J. S. Targeting CYP17: Established and novel approaches in prostate cancer. Curr. Opin. Pharmacol. 8, 449-457 (2008).
4. Vasaitis, T. S., Bruno, R. D. & Njar, V. C. CYP17 inhibitors for prostate cancer therapy. J. Steroid Biochem. Mol. Biol. 125, 23-31 (2011).
5. de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005 (2011).
6. Molina, A. & Belidegrun, A. Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling. J. Urol. 185, 787-794 (2011).
7. Auchus, R. J., Geller, D. H., Lee, T. C. & Miller, W. L. The regulation of human P450c17 activity: relationship to premature adrenarche, insulin resistance and the polycystic ovary syndrome. Trends Endocrinol. Metab. 9, 47-50 (1998). (Pubitemid 28207611)
8. Attard, G. et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 26, 4563-4571 (2008).
9. Brodie, A., Njar, V., Macedo, L. F., Vasitis, T. S. & Sabnis, G. The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer. Urol. Oncol. 27, 53-63 (2009).
10. Imai, T. et al. Expression and purification of functional human 17a-hydroxylase/17, 20-lyase (P450c17) in Escherichia coli. Use of this system for study of a novel form of combined 17a-hydroxylase/17, 20-lyase deficiency. J. Biol. Chem. 268, 19681-19689 (1993). (Pubitemid 23270759)
11. Huang, P., Chandra, V. & Rastinejad, F. Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics. Annu. Rev. Physiol. 72, 247-272 (2010).
12. Pereira de Jésus-Tran, K. et al. Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Protein Sci. 15, 987-999 (2006).
13. Vasaitis, T. et al. Androgen receptor inactivation contributes to antitumor efficacy of 17a-hydroxylase/17, 20-lyase inhibitor 3b-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5, 16-diene in prostate cancer. Mol. Cancer Ther. 7, 2348-2357 (2008).
14. Ghosh, D., Griswold, J., Erman, M. & Pangborn, W. Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature 457, 219-223 (2009).
15. Mast, N. et al. Structural basis for three-step sequential catalysis by the cholesterol side chain cleavage enzyme CYP11A1. J. Biol. Chem. 286, 5607-5613 (2011).
16. Mast, N. et al. Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain. Proc. Natl Acad. Sci. USA 105, 9546-9551 (2008). (Pubitemid 352031338)
17. Dhir, V. et al. Steroid 17a-hydroxylase deficiency: Functional characterization of four mutations (A174E, V178D, R440C, L465P) in the CYP17A1 gene. J. Clin. Endocrinol. Metab. 94, 3058-3064 (2009).
18. Rosa, S. et al. Clinical, genetic and functional characteristics of three novel CYP17A1 mutations causing combined 17a-hydroxylase/17, 20-lyase deficiency. Horm. Res. Paediatr. 73, 198-204 (2010).
19. Katsumata, N., Ogawa, E., Fujiwara, I. & Fujikura, K. Novel CYP17A1 mutation in a Japanese patient with combined 17a-hydroxylase/17, 20-lyase deficiency. Metabolism 59, 275-278 (2010).
20. Ergun-Longmire, B. et al. Two novel mutations found in a patient with 17ahydroxylase enzyme deficiency. J. Clin. Endocrinol. Metab. 91, 4179-4182 (2006). (Pubitemid 44536903)
21. Sahakitrungruang, T., Tee, M. K., Speiser, P. W. & Miller, W. L. Novel P450c17 mutation H373D causing combined 17a-hydroxylase/17, 20-lyase deficiency. J. Clin. Endocrinol. Metab. 94, 3089-3092 (2009).
22. Biason-Lauber, A. et al. 17a-hydroxylase/17, 20-lyase deficiency as a model to study enzymatic activity regulation: role of phosphorylation. J. Clin. Endocrinol. Metab. 85, 1226-1231 (2000). (Pubitemid 32269377)
23. Lee-Robichaud, P. et al. The cationic charges on Arg347, Arg358 and Arg449 of human cytochrome P450c17 (CYP17) are essential for the enzyme's cytochrome b5-dependent acyl-carbon cleavage activities. J. Steroid Biochem. Mol. Biol. 92, 119-130 (2004). (Pubitemid 39535853)
24. Gupta, M. K., Geller, D. H. & Auchus, R. J. Pitfalls in characterizing P450c17 mutations associated with isolated 17, 20-lyase deficiency. J. Clin. Endocrinol. Metab. 86, 4416-4423 (2001). (Pubitemid 32848568)
25. Tiosano, D. et al. Metabolic evidence for impaired 17a-hydroxylase activity in a kindred bearing the E305G mutation for isolate 17, 20-lyase activity. Eur. J. Endocrinol. 158, 385-392 (2008). (Pubitemid 351405004)
26. Auchus, R. J., Lee, T. C. & Miller, W. L. Cytochrome b5 augments the 17, 20-lyase activity of human P450c17 without direct electron transfer. J. Biol. Chem. 273, 3158-3165 (1998). (Pubitemid 28109723)
27. Swart, A. C., Storbeck, K. H. & Swart, P. A single amino acid residue, Ala 105, confers 16a-hydroxylase activity to human cytochrome P450 17a-hydroxylase/17, 20 lyase. J. Steroid Biochem. Mol. Biol. 119, 112-120 (2010).
28. Haider, S. M., Patel, J. S., Poojari, C. S. & Neidle, S. Molecular modeling on inhibitor complexes and active-site dynamics of cytochrome P450 C17, a target for prostate cancer therapy. J. Mol. Biol. 400, 1078-1098 (2010).
29. Jagusch, C. et al. Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17ahydroxylase-17, 20-lyase (CYP17). Part I: heterocyclic modifications of the core structure. Bioorg. Med. Chem. 16, 1992-2010 (2008). (Pubitemid 351226569)
30. Pechurskaya, T. A., Lukashevich, O. P., Gilep, A. A. & Usanov, S. A. Engineering, expression, and purification of "soluble" human cytochrome P45017a and its functional characterization. Biochemistry 73, 806-811 (2008).
31. Leslie, A. G. W. MOSFLM 6. 0 (Cambridge, 1998).
32. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D 50, 760-763 (1994).
33. Long, F., Vagin, A. A., Young, P. & Murshudov, G. N. BALBES: a molecular replacement pipeline. Acta Crystallogr. D 64, 125-132 (2008).
34. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60, 2126-2132 (2004). (Pubitemid 41742764)
35. Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D 53, 240-255 (1997). (Pubitemid 27235885)
36. Hooft, R. W., Vriend, G., Sander, C. & Abola, E. E. Errors in protein structures. Nature 381, 272 (1996).
37. Laskowski, R. A., MacArthur, M. W., Moss, D. S. & Thornton, J. M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26, 283-291 (1993).
38. DeVore, N. M. et al. Key residues controlling binding of diverse ligands to human cytochrome P450 2A enzymes. Drug Metab. Dispos. 37, 1319-1327 (2009).
39. DeLano, W. L. The PyMol Molecular Graphics System (DeLano Scientific, 2002).
40. Kleywegt, G. J. & Jones, T. A. Detection, delineation, measurement and display of cavities in macromolecular structures. Acta Crystallogr. D 50, 178-185 (1994). (Pubitemid 2054290)
41. Jain, A. N. Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. J. Med. Chem. 46, 499-511 (2003). (Pubitemid 36182752)
42. Hutschenreuter, T. U., Ehmer, P. B. & Hartmann, R. W. Synthesis of hydroxy derivatives of highly potent non-steroidal CYP 17 inhibitors as potential metabolites and evaluation of their activity by a non cellular assay using recombinant human enzyme. J. Enzyme Inhib. Med. Chem. 19, 17-32 (2004). (Pubitemid 38239927)
43. Shen, A. L., Porter, T. D., Wilson, T. E. & Kasper, C. B. Structural analysis of the FMN binding domain of NADPH-cytochrome P-450 oxidoreductase by site-directed mutagenesis. J. Biol. Chem. 264, 7584-7589 (1989). (Pubitemid 19119176)